Avelumab, Merck KGaAs and Pfizers Phase III checkpoint inhibitor, has been granted Priority Review from the US Food and Drug Administration in urothelial carcinoma patients who progressed on or after platinum-based chemotherapy.
The times in which biotechs dominate the orphan drug market are over. A report from business intelligence provider Evaluate Ltd. concludes that only three in ten OD developers are still biotech SMEs.
Henrik Luessen is taking over as Chief Business Officer at Promethera Biosciences SA, Belgian developer of cell-based meds. He will be responsible for identifying and executing strategic corporate development initiatives and licensing agreements.
https://european-biotechnology.com/wp-content/uploads/2024/04/henrik-luessen.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-02-27 16:44:172017-02-27 16:44:17Promethera Biosciences: Boss of business
Lund-based probiotics expert Probi AB has appointed Jörn Andreas as new CFO. He will replace Niklas Brandt, who in turn will take over responsibility for IT infrastructure and IR as CIO.
https://european-biotechnology.com/wp-content/uploads/2024/04/20170227-berlin-conference.jpg450800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-02-27 15:47:442017-02-27 15:47:44European dynamics in AMR
Several promising antibiotic candidates, developed by ENABLE and its partners, are rapidly approaching the pre-clinical development stage. The European consortium is now seeking new partners to proceed with non-clinical studies.
BaseLaunch, a new life sciences accelerator in Basel, has been kicked off. Its mission: to bring the most promising healthcare projects and ventures to Europes leading life sciences hub.
https://european-biotechnology.com/wp-content/uploads/2024/04/BASELAUNCH_0155.jpg12781920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-02-23 05:26:222017-02-23 05:26:22Kick off for BaseLaunch accelerator
While governments worldwide discuss to pay premiums to pharma companies offering novel antibiotics that fight multiresistant pathogens, Roche has extended its discovery deal with British Discuva Ltd.
Pfizers Cyprus Business Manager Kyriakos Mikellis has been re-elected for the next two years as president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA).
https://european-biotechnology.com/wp-content/uploads/2024/04/kyriakos-mikellis.jpg393349h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-02-21 10:33:302017-02-21 10:33:30KEFEA: Re-elected president
FDA grants Priority Review to avelumab
Latest NewsAvelumab, Merck KGaAs and Pfizers Phase III checkpoint inhibitor, has been granted Priority Review from the US Food and Drug Administration in urothelial carcinoma patients who progressed on or after platinum-based chemotherapy.
Big Pharma pushing up orphan drug prices
Latest NewsThe times in which biotechs dominate the orphan drug market are over. A report from business intelligence provider Evaluate Ltd. concludes that only three in ten OD developers are still biotech SMEs.
Promethera Biosciences: Boss of business
AppointmentsHenrik Luessen is taking over as Chief Business Officer at Promethera Biosciences SA, Belgian developer of cell-based meds. He will be responsible for identifying and executing strategic corporate development initiatives and licensing agreements.
Probi: Handle on finances
AppointmentsLund-based probiotics expert Probi AB has appointed Jörn Andreas as new CFO. He will replace Niklas Brandt, who in turn will take over responsibility for IT infrastructure and IR as CIO.
European dynamics in AMR
Latest NewsAround 130 antibiotics experts joined the 10th Berlin Conference on 24th February to highlight high dynamics of European AMR activities.
Oncopeptides raises €68m in IPO
Latest NewsSwedish cancer med developer Oncopeptides AB has raised SEK649m (€68m) in an IPO at Nasdaq Stockholm.
Funding: ENABLE goes pre-clinical
Latest NewsSeveral promising antibiotic candidates, developed by ENABLE and its partners, are rapidly approaching the pre-clinical development stage. The European consortium is now seeking new partners to proceed with non-clinical studies.
Kick off for BaseLaunch accelerator
Latest NewsBaseLaunch, a new life sciences accelerator in Basel, has been kicked off. Its mission: to bring the most promising healthcare projects and ventures to Europes leading life sciences hub.
Roche extends antibiotics collaboration
Latest NewsWhile governments worldwide discuss to pay premiums to pharma companies offering novel antibiotics that fight multiresistant pathogens, Roche has extended its discovery deal with British Discuva Ltd.
KEFEA: Re-elected president
Appointments